These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Soluble Urokinase Receptor and Chronic Kidney Disease. Hayek SS; Sever S; Ko YA; Trachtman H; Awad M; Wadhwani S; Altintas MM; Wei C; Hotton AL; French AL; Sperling LS; Lerakis S; Quyyumi AA; Reiser J N Engl J Med; 2015 Nov; 373(20):1916-25. PubMed ID: 26539835 [TBL] [Abstract][Full Text] [Related]
9. Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. Persson F; Theilade S; Eugen-Olsen J; Rossing P; Parving HH J Diabetes Complications; 2016; 30(8):1440-1442. PubMed ID: 27475262 [TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. Persson M; Engström G; Björkbacka H; Hedblad B Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508 [TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Persson M; Östling G; Smith G; Hamrefors V; Melander O; Hedblad B; Engström G Stroke; 2014 Jan; 45(1):18-23. PubMed ID: 24253546 [TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications. Sherif EM; El Maksood AAA; Youssef OI; Salah El-Din NY; Khater OKM J Diabetes Complications; 2019 Sep; 33(9):628-633. PubMed ID: 31301955 [TBL] [Abstract][Full Text] [Related]
14. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease. Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848 [TBL] [Abstract][Full Text] [Related]
16. suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. Theilade S; Rossing P; Eugen-Olsen J; Jensen JS; Jensen MT Eur J Endocrinol; 2016 Jun; 174(6):745-53. PubMed ID: 26951602 [TBL] [Abstract][Full Text] [Related]
17. Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Jenkins AJ; Steele JS; Janus ED; Santamaria JD; Best JD Diabetologia; 1992 Nov; 35(11):1055-9. PubMed ID: 1473615 [TBL] [Abstract][Full Text] [Related]
18. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study. Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J; Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800 [TBL] [Abstract][Full Text] [Related]
19. Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery. Mossanen JC; Pracht J; Jansen TU; Buendgens L; Stoppe C; Goetzenich A; Struck J; Autschbach R; Marx G; Tacke F Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758975 [TBL] [Abstract][Full Text] [Related]
20. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. von Scholten BJ; Persson F; Rosenlund S; Eugen-Olsen J; Pielak T; Faber J; Hansen TW; Rossing P Diabetes Obes Metab; 2017 Jun; 19(6):901-905. PubMed ID: 28105731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]